Results 1 to 10 of about 2,712 (224)

Clinical experience on switching trientine tetrahydrochloride to trientine dihydrochloride in Wilson disease patients. [PDF]

JIMD Rep
This study evaluates the effectiveness and safety of trientine dihydrochloride (TETA 2‐HCl) in patients with Wilson disease (WD) following a switch from trientine tetrahydrochloride (TETA 4‐HCl).
Mohr I, Schmitt T, Weber C, Schall N, Leidner VY, Langel A, Langel J, Poujois A, Weiss KH, Merle U.   +9 more
europepmc   +5 more sources

Safety of penicillamine and trientine in the treatment of Wilson's disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]

PLoS One
BackgroundPenicillamine(D-Penicillamine) and trientine are first-line therapies for Wilson's Disease (WD), yet real-world data on their adverse events (AEs) remain scarce.
Qian W, Xu K, Li S, Zhang Z, Hou X, Min B, Ling J, Zhu X, Zhou H, Xu W, Yang W, Cao S, Chen Y.   +12 more
europepmc   +4 more sources

Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine Dihydrochloride in Patients With Wilson Disease. [PDF]

JGH Open
Background and Aims Wilson disease is an inherited disorder of copper metabolism affecting mainly the liver and brain. Trientine dihydrochloride (TETA‐2HCl) is approved for the treatment of Wilson disease in patients (≥ 5 years) intolerant to D ...
Mohr I, Kruse C, Aliane V, Weiss KH.
europepmc   +3 more sources

Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients. [PDF]

Orphanet J Rare Dis
Objectives Wilson disease (WD) is a rare genetic disease affecting copper metabolism and the biliary tract’s copper excretion. Lifelong medication is necessary to prevent liver failure, neurological complications, and death. Although D-penicillamine (DPA)
Lee EJ, Woo MH, Moon JS, Ko JS.
europepmc   +3 more sources

Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase. [PDF]

Orphanet J Rare Dis
Introduction Wilson’s disease is a rare autosomal copper metabolism recessive disorder that requires lifelong pharmacological treatment. D-penicillamine and trientine are the most commonly used copper chelators.
Tezel-Yalçın H, Yalçın N, Allegaert K, Erkekoğlu P.   +3 more
europepmc   +2 more sources

Comparative management practices of Wilson disease in Californian and Italian providers. [PDF]

J Health Popul Nutr
Background There is a scarcity of randomized and high-quality studies to aid clinicians in management and treatment of Wilson disease (WD). Even amongst society practice guidelines in North America and Europe, diagnosis and management of WD varies.
Vien S, McNamara C, Hsu R, Zuin M, Medici V.   +4 more
europepmc   +2 more sources

Wilson Disease Hiding in Plain Sight: A Case Report of Psychosis and Catatonia Revealing Underlying Liver Dysfunction. [PDF]

Reports (MDPI)
Background and Clinical Significance: Wilson disease is a rare autosomal recessive disorder of copper metabolism that can initially present with psychiatric symptoms, leading to delays in accurate diagnosis and treatment.
Buciuc AG, Padilla V, Durand D, Zelde E.
europepmc   +2 more sources

Treatment patterns in a real-world cohort of patients with Wilson disease in the United States. [PDF]

Front Gastroenterol (Lausanne)
BackgroundWilson disease (WD) is a rare and potentially fatal genetic disorder caused by accumulation of toxic levels of copper. Current treatments include chelating agents and/or zinc.
Medici V, Kebede N, Stephens J, Kunjappu M, Vierling JM.   +4 more
europepmc   +2 more sources

Alterations of lipid metabolism in Wilson disease [PDF]

Lipids in Health and Disease, 2011
Introduction Wilson disease (WD) is an inherited disorder of human copper metabolism, characterised by accumulation of copper predominantly in the liver and brain, leading to severe hepatic and neurological disease.
Stremmel Wolfgang, Eckert Nicola, Pfeiffenberger Jan, Gotthardt Daniel, Gohdes Annina, Seessle Jessica, Reuner Ulrike, Weiss Karl   +7 more
doaj   +3 more sources

A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy

Frontiers in Oncology, 2019
Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-resistant cancer cells by enhancing the human copper ...
Yu-Fang Huang, Pei-Ying Wu, Cheng-Yang Chou   +2 more
exaly   +3 more sources